Recent study Hepatitis Drugs In Development Pipeline Therapeutics Assessment 2017 report provides Hepatitis A, Hepatitis B, Hepatitis C, and Hepatitis D Drugs and Therapeutics development by pharmaceutical companies. Report provides more than 100 pharmacy companies Hepatitis A, Hepatitis B, Hepatitis C, and Hepatitis D pipeline analysis.
Hepatitis Drug Development Pipeline Therapeutics Review 2017 provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.
Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications.The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting.
Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology is fielding two pipeline products in this area, while all other companies are fielding only one.
In hepatitis D there are a total of 12 products in development, by nine companies and one academic institution. Key companies operating in this pipeline space include EigerBioPharmaceuticalsand Replicor.
Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both.
There are a total of 182 products in development for hepatitis B, by 110 companies and 14 academic institutions. Key companies operating in this pipeline space include Arbutus Biopharma, F.
Hoffmann-La Roche, Johnson & Johnson, Assembly Biosciences, Gilead Sciences and InstitutoButantan. There are a total of 199 products in development for hepatitis C, by 92 companies and 34 academic institutions.
Key companies operating in this pipeline space include Merck & Co, AbbVie, Johnson & Johnson, Gilead Sciences, Cocrystal Pharma, Bristol-Myers Squibb and F. Hoffmann-La Roche. While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.
Report helps to understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication. Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these. Understand the composition of the pipeline in terms of molecule type, molecular target, and mechanism of action and route of administration.
Report provides information on Following-
- Which companies are the most active within the pipeline for hepatitis therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of hepatitis?